Login to your account
Don’t have an account?
Create a Free AccountEditor's Choice Archive
A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with cancer [1]. Both pathologies interrelate at a deep biological level with numerous interactions between key elements of the hemostatic system and cancer cell programs [2]. Cancer-associated thrombosis (CAT) falls within a panorama of growing complexity in oncology, with the appearance of new anticoagulant therapies, emerging molecular data [3], and new antineoplastic treatments associated with thrombotic risk.
